CN110462024B - 用于癌症免疫疗法的mr1限制性t细胞受体 - Google Patents

用于癌症免疫疗法的mr1限制性t细胞受体 Download PDF

Info

Publication number
CN110462024B
CN110462024B CN201880016990.4A CN201880016990A CN110462024B CN 110462024 B CN110462024 B CN 110462024B CN 201880016990 A CN201880016990 A CN 201880016990A CN 110462024 B CN110462024 B CN 110462024B
Authority
CN
China
Prior art keywords
ser
leu
val
cell
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880016990.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN110462024A (zh
Inventor
加纳罗·得利博罗
马尔科·莱波雷
露西娅·莫利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitaet Basel
Original Assignee
Universitaet Basel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitaet Basel filed Critical Universitaet Basel
Publication of CN110462024A publication Critical patent/CN110462024A/zh
Application granted granted Critical
Publication of CN110462024B publication Critical patent/CN110462024B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201880016990.4A 2017-03-07 2018-03-07 用于癌症免疫疗法的mr1限制性t细胞受体 Active CN110462024B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP17159754.5 2017-03-07
EP17159754 2017-03-07
EP17179309 2017-07-03
EP17179309.4 2017-07-03
PCT/EP2018/055620 WO2018162563A1 (en) 2017-03-07 2018-03-07 Mr1 restricted t cell receptors for cancer immunotherapy

Publications (2)

Publication Number Publication Date
CN110462024A CN110462024A (zh) 2019-11-15
CN110462024B true CN110462024B (zh) 2024-08-09

Family

ID=61563412

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880016990.4A Active CN110462024B (zh) 2017-03-07 2018-03-07 用于癌症免疫疗法的mr1限制性t细胞受体

Country Status (9)

Country Link
EP (2) EP3592839B1 (enExample)
JP (2) JP7233103B2 (enExample)
KR (1) KR20190126332A (enExample)
CN (1) CN110462024B (enExample)
AU (1) AU2018231405B2 (enExample)
CA (1) CA3054758A1 (enExample)
IL (1) IL268813A (enExample)
WO (1) WO2018162563A1 (enExample)
ZA (1) ZA201905579B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4099015A1 (en) 2016-06-10 2022-12-07 Gadeta B.V. Novel method for identifying deltat-cell (or gammat-cell) receptor chains or parts thereof that mediate an anti-tumour or an anti-infective response
AU2018268087B2 (en) 2017-05-18 2022-03-17 Umc Utrecht Holding B.V. Compositions and methods for cell targeting therapies
GB201717578D0 (en) 2017-10-26 2017-12-13 Univ College Cardiff Consultants Ltd Novel T-cell receptor
JP7469807B2 (ja) * 2018-04-19 2024-04-17 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Ｍａｇｅ－ｂ２特異性を有するｔ細胞受容体およびその使用
BR112021003996A2 (pt) * 2018-09-12 2021-05-25 Universität Basel receptores de célula t restritos à mr1 para imunoterapia contra o câncer
SG11202105975SA (en) * 2018-12-06 2021-07-29 Guangdong Tcrcure Biopharma Technology Co Ltd Combinational tcr-t cell therapy targeting tumor antigens, tgf-beta, and immune checkpoints
WO2022118043A1 (en) 2020-12-03 2022-06-09 Enara Bio Limited Novel protein-ligand complex
WO2022248881A1 (en) 2021-05-28 2022-12-01 Enara Bio Limited Novel protein-ligand complex
KR20230088292A (ko) * 2021-12-10 2023-06-19 주식회사 유틸렉스 MR1 제한적 Panck T 세포 및 이의 제조방법
WO2023148494A1 (en) * 2022-02-03 2023-08-10 University College Cardiff Consultants Limited Novel t-cell receptor
CN119587561B (zh) * 2024-12-09 2025-11-28 新乡医学院 THP在制备增强Vγ9Vδ2 T细胞抗肿瘤疗效的药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014160030A2 (en) * 2013-03-13 2014-10-02 Health Research, Inc. Compositions and methods for use of recombinant t cell receptors for direct recognition of tumor antigen

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2089229C (en) * 1992-02-14 2010-04-13 Alejandro A. Aruffo Cd40cr receptor and ligands therefor
US7829289B2 (en) * 2002-05-14 2010-11-09 Institut National De La Sante Et De Recherche Medicale T cell subpopulation regulating gut immunity
JP6126804B2 (ja) * 2012-07-25 2017-05-10 国立大学法人富山大学 Ｔ細胞受容体のクローニング方法
WO2015149130A1 (en) * 2014-04-01 2015-10-08 The University Of Queensland Immunological reagents and uses therefor

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014160030A2 (en) * 2013-03-13 2014-10-02 Health Research, Inc. Compositions and methods for use of recombinant t cell receptors for direct recognition of tumor antigen

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Clinical relevance of circulating mucosal-associated invariant T cell levels and their anti-cancer activity in patients with mucosal-associated cancer;Eun Jeong Won 等;《Oncotarget》;20161115;第7卷(第46期);摘要 *
FUNCTIONALLY DIVERSE HUMAN T CELLS RECOGNIZE NON-MICROBIAL ANTIGENS PRESENTED BY MR1;MARCO LEPORE 等;《ELIFE》;20170518;第6卷;e24476 1-22 *
Lepore,M.et al..Parallel T-cell cloning and deep sequencing of human MAIT cells reveal stable oligoclonal TCRβ repertoire.《NATURE COMMUNICATIONS》.2014,第5卷第3866篇. *

Also Published As

Publication number Publication date
WO2018162563A1 (en) 2018-09-13
CN110462024A (zh) 2019-11-15
EP4273233A3 (en) 2023-11-15
ZA201905579B (en) 2024-08-28
JP2020527036A (ja) 2020-09-03
KR20190126332A (ko) 2019-11-11
AU2018231405A1 (en) 2019-09-26
IL268813A (en) 2019-10-31
JP7515209B2 (ja) 2024-07-12
CA3054758A1 (en) 2018-09-13
JP2023058659A (ja) 2023-04-25
EP3592839C0 (en) 2023-07-05
EP3592839A1 (en) 2020-01-15
AU2018231405B2 (en) 2024-02-08
EP4273233A2 (en) 2023-11-08
EP3592839B1 (en) 2023-07-05
JP7233103B2 (ja) 2023-03-06

Similar Documents

Publication Publication Date Title
CN110462024B (zh) 用于癌症免疫疗法的mr1限制性t细胞受体
CN110785432B (zh) Tcr和肽
US20170313759A1 (en) Novel chimeric antigen receptors
KR20220147109A (ko) 키메라 항원 수용체 발현 세포의 제조 방법
KR20140127816A (ko) 암의 치료에 유용한 t 세포의 지속성 집단을 생성시키기 위한 조성물 및 방법
CN112673018A (zh) 用于癌症免疫疗法的mr1限制性t细胞受体
JP2022513390A (ja) Ｔｃｒ及びペプチド
Yao et al. Isolation and characterization of an HLA-DPB1* 04: 01-restricted MAGE-A3 T-cell receptor for cancer immunotherapy
KR20200064126A (ko) 면역요법을 위한 t 세포 수용체
US11702459B2 (en) MR1 restricted T cell receptors for cancer immunotherapy
JP7018387B2 (ja) 腫瘍標的療法のためのｃｘｃｒ６形質導入ｔ細胞
CN110461881A (zh) 嵌合抗原受体
de Kleer et al. CD30 discriminates heat shock protein 60-induced FOXP3+ CD4+ T cells with a regulatory phenotype
CN111197032A (zh) 嵌合抗原受体细胞分泌治疗剂
JP6842688B2 (ja) キメラ抗原受容体
CA3141210A1 (en) Modified nk-92 cells, and therapeutic and diagnostic uses thereof
US20240002465A1 (en) Mr1 restricted t cell receptors for cancer immunotherapy
CN113631172B (zh) 用于靶向突变型ras的组合物和方法
AL-SULAITI GENERATION AND CHARACTERIZATION OF" OFF-THE-SHELF" CHIMERIC ANTIGEN RECEPTOR ENGINEERED T CELLS (CAR-T) TO TARGET CANCER PATIENTS WITH HEMATOLOGICAL MALIGNANCIES
WO2026003364A1 (en) Chimeric coreceptors
CN117980324A (zh) 特异性结合ct45的抗原结合蛋白
CN113631172A (zh) 用于靶向突变型ras的组合物和方法
HK40024455A (en) Tcr and peptides

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant